Publication | Closed Access

First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients

ObesityMetabolic SyndromeDiabetes ManagementHepatologyNonalcoholic Steatohepatitis PatientsInsulin ManagementDiabetesDiabetes MellitusFirst-in-asian Double-blindFatty Liver DiseaseInsulin SensitizerMedicine